DLH Holdings Corp. (DLHC) stock intrinsic value fair value estimate & owner earnings analysis

DLH Holdings provides services to US federal agencies. In fiscal 2025 (year to September 30) revenue was $344.5 million: about half from the Department of Health and Human Services, $116.4 million (34%) from the Department of Veterans Affairs, and $53.2 million (15%) from the Department of Defense. The Veterans Affairs revenue is entirely pharmacy and logistics work for its Consolidated Mail Outpatient Pharmacy program. WHAT HAS HAPPENED TO THE BUSINESS. Two large pieces of that revenue are being lost. The VA has re-bid the eight pharmacy locations as set-asides for service-disabled veteran-owned small businesses; by the annual report it had awarded three task orders to unaffiliated winners and one location moved to a new prime contractor on November 30, 2025. DLH holds a sole-source contract with a $90 million ceiling effective October 28, 2025, with orders through October 2026 that can extend performance to April 2027, so some of this work continues for now. Separately, a $37.6 million Head Start monitoring contract (10.9% of fiscal 2025 revenue) ended October 31, 2025 for the same kind of reason. Revenue excluding the pharmacy and Head Start work was about $190.5 million in fiscal 2025. The company's own risk disclosure says it could lose more work to small-business set-asides. Reported contract backlog fell from $690.3 million to $514.3 million over fiscal 2025, but that figure still includes contracts being lost, so we do not rely on it. The June 2026 quarter shows the effect. Revenue was $44.2 million against $83.3 million a year earlier. Contract costs were 83% of revenue (81% in fiscal 2025), and overhead (general and administrative cost) was $7.3 million against $7.6 million a year earlier, so overhead has barely moved while revenue has nearly halved. After $4.0 million of depreciation and amortization the quarter had an operating loss of $3.9 million, which means earnings before depreciation and amortization were roughly zero. Over nine months revenue was $172.4 million against $263.3 million and the company wrote off $9.1 million of deferred tax assets, which signals that management does not expect near-term taxable profit. HOW WE MEASURE EARNINGS. We use cash from operations, remove swings in working capital, and deduct stock compensation and the equipment spending needed to stay in business. Depreciation and amortization (about $17 million a year, almost all amortization of acquired contracts) is non-cash and is added back; we do not also deduct it. On that basis earnings per share were $0.30 (fiscal 2016), $0.50, $0.72, $0.90, $1.30, $1.49, $2.23 (fiscal 2022), $1.50, $1.55 and $1.27 (fiscal 2025), and $0.16 for the first nine months of fiscal 2026. Fiscal 2021 cash flow was inflated, and fiscal 2022 correspondingly depressed, by $22.3 million of customer billings received in advance and then recognized as revenue; removing working capital puts that in the right year. The fiscal 2023 to 2025 median of $1.50 describes a company with roughly twice today's revenue, so we do not use it as the starting level. Instead each case is built from the revenue that remains. Fiscal 2025 earnings fell 18% from fiscal 2024; our base case has the first year of cash flow slightly negative, lower than that trend, with no reversal assumed. WHAT THE BUSINESS OWES. At June 30, 2026 borrowings were $128.7 million against $0.2 million of cash. About $115.0 million is a term loan secured by substantially all assets, with $15.25 million scheduled over the next twelve months and the remaining $99.75 million due, with the balance, at maturity in December 2027. The maturity table also showed $13.7 million falling due before the September 30, 2026 year-end; we could not see how that was settled. The loan requires a fixed-charge coverage of at least 1.15 times and a leverage ratio that steps down toward 2.0 times by maturity. Operating income plus depreciation and amortization over the twelve months to June 2026 was $16.6 million, or about 7.8 times the debt, and that figure still includes stronger early quarters. Interest runs near 8.3% a year (about $2.7 million in the June quarter), above the 4.10% fixed swap that expired January 31, 2026. Because it costs more than a long-term bond rate, we add about $3.3 million to the debt figure, making what is owed about $131.9 million, or about $9.10 a share on 14.5 million shares. THE CASES. Each case is valued as a business first, then the debt is subtracted. We give no credit to growth, new awards or acquisitions in any case: nothing signed supports them, and the company's past growth came from buying contractors with borrowed money, which its present debt rules out. Bear: revenue settles near $130 million as more HHS and Defense work goes to small-business set-asides, contract margin stays at the June-quarter 17%, and overhead cannot fall below about $22 million, which is what it ran at when revenue was $160 million in fiscal 2019. Earnings before depreciation and amortization are then about zero, the $115 million balloon in December 2027 cannot be refinanced, and lenders take control. The business is worth about nothing against about $131.9 million owed, a shortfall of about $9.10 a share. The company appears to owe far more than it is worth. Base: revenue settles near $160 million. The June quarter, annualized, is $177 million but still includes pharmacy work that can end by April 2027, and fiscal 2025 revenue excluding the lost work was $190.5 million, which the latest quarter is already below. Contract margin is 17.5%, between the June quarter's 16.7% and the nine-month 18.7%. Overhead falls from the current $29 million a year to about $22 million by fiscal 2028, the level the company ran at similar size in fiscal 2019 ($20.5 million at $160 million of revenue). That gives about $6 million of earnings before depreciation and amortization and, after stock compensation of about $1.4 million, taxes of about $1 million and capital spending of about $0.25 million, roughly $3.3 million a year of cash for the business before paying lenders, held for ten years and at half that for the following ten as contracts are re-competed. The business is worth about $25 million against about $131.9 million owed, a shortfall of about $106 million, or about $7.34 a share. On this case the debt cannot be repaid from the business and a restructuring leaves shareholders with little. Bull: the June-quarter revenue of $177 million holds, contract margin returns to the 19% of fiscal 2024 and 2025 (19.6% and 18.9%), and overhead is cut to $20 million. That is about $13.6 million of earnings before depreciation and amortization and about $10.4 million a year of cash, held for twenty years because the company states its major customers have historically exercised renewal options. The business is worth about $109 million against about $131.9 million owed, a shortfall of about $23 million, or about $1.56 a share. Even this case leaves the shares worth less than the debt. TESTING THE CASE. The most important assumption is how little cash the remaining business produces. We checked whether the retained work could be larger than assumed: fiscal 2025 revenue excluding the lost work averaged $47.6 million a quarter, but the June 2026 quarter was $44.2 million including whatever pharmacy work remains, so the retained base has already shrunk. We checked whether overhead is already coming down: nine-month overhead was $22.1 million against $23.9 million a year earlier, down 8% while revenue fell 34%. Both facts support the cases above. Quarterly figures come from the company's structured filing data; we could not read the text of the latest quarterly report, so covenant waivers or management plans described there are not reflected. Our level rests mainly on one quarter, which is why confidence is low. WHAT COULD MAKE THIS WRONG. The cases are most exposed to overhead. Each $1.5 million a year of extra cash flow adds about $0.8 a share, and the shares would only turn positive in the base case with roughly $10 million more annual cash flow than we assume, which would need overhead near $14 million or revenue and margins back at pre-loss levels. A refinancing on ordinary terms, or large contract awards backed by signed paper, would change the picture; neither is in the filings. MARGIN-OF-SAFETY PRICE. We are not confident of the earnings level: it rests on one weak quarter and a lender that holds a lien on substantially all assets and is owed a $115 million balloon in December 2027. The worst plausible outcome is that lenders take the company and the shares are worth nothing; the business has no hard assets to cushion that. On today's facts no margin-of-safety price applies. If the loan were refinanced or extended to 2030 or later without heavy share issuance, and the company showed four quarters totalling at least $20 million of earnings before depreciation and amortization, the business would produce about $17 million a year of cash and the shares would be worth roughly $2.40. Because a $3 million annual shortfall from that level would take most of the value away, and because the price assumes a holding period of about three years with no cash returned to shareholders while the debt is paid down, the margin-of-safety price is about $1.00 once those conditions are met, and does not apply before. The earlier estimates for this company were made on a different basis and are not comparable. What has changed in our view of the business is that a recovery in margins and growth is no longer assumed, because the latest quarter shows overhead of $7.3 million against $44 million of revenue.